The recent rise in the incidence of thyroid cancer may be due to the increase in identification of low-risk papillary thyroid cancers through the use of ultrasound and/or biopsy. Most of these small, low-risk thyroid cancers (tumors < 1 cm) do not grow or grow very slowly. A new management strategy for low-risk thyroid cancers, […]
Anaplastic thyroid cancer is a very aggressive and rare form of thyroid cancer. The US Food and Drug Administration has approved the use of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) administered together to treat anaplastic thyroid cancer that cannot be surgically removed or has spread to other locations in the body, and is BRAF V600E […]
We are pleased to announce that an article featuring the Thyroid Care Collaborative (TCC) has been published in the International Journal of Endocrine Oncology. The article describes all of the ways in which the TCC can be used a method of facilitating the multidisciplinary management of thyroid cancer.
The TCC is proud to be attending the 2oth annual THYCA (Thyroid Cancer Survivors’ Association) conference in Baltimore, MD October 6-8, 2017. We are also very excited to be able to help THYCA members get their records into the TCC for safekeeping, better coordination between their doctors, and research. THYCA is reaching out to its […]